Zimmer Biomet is trading roughly flat today, supported by the announcement on October 13 that the company extended its exclusive distribution agreement with THINK Surgical. This partnership aims to accelerate the adoption of the TMINI handheld system for use with the Persona knee portfolio. Investor sentiment remains bolstered by recent analysis highlighting the stock as an attractive value play, citing a P/E ratio of 11.98 compared to the industry average of 15.93.